Eye on FDA

APRIL 17, 2020

In response to written questions submitted last month regarding the potential for delays, FDA had stated that “ CDER remains fully capable to continue daily activities, while responding to the public needs of the current COVID-19 outbreak. ” In a subsequent blog posting this month, it was noted that FDA was devoting personnel to focus on COVID-19-related review efforts and that it was certainly possible that this might be a factor in delaying new approvals of non-COVID-19 medicines a

Documentation 55

Documentation Communication 55

Med Ed 101

APRIL 15, 2020

There are some scary things happening across the country with regards to COVID-19 infections. One of the biggest risks is to our geriatric population. I’ve heard reports all over the place on this topic and concerns are likely heavily dependent upon the region you are in. One of the questions I’m asking myself is, how […]. The post Reducing Medication Burden and Risks in COVID-19 appeared first on Med Ed 101.

40

40

Eye on FDA

APRIL 15, 2020

As the coronavirus pandemic began to unfold, focus on the pharmaceutical and biotech sectors was on the most immediate and apparent concerns – the impact on the supply chain for drugs that are currently in the market and on the regulatory process for approving new ones. More distant in time, but also of extreme importance is the effect on the launch of new medicines that have been approved.

Vaccines 55

Vaccines 55

Med Ed 101

APRIL 12, 2020

Lithium is one of the most complex medications one of your patients can be on. Between drug interactions, monitoring parameters, and managing bipolar disorder, it is easy to get overwhelmed by the complexity. Here are a few lithium clinical pearls I always think about when I see an order for the medication. Some of the […]. The post Lithium Clinical Pearls appeared first on Med Ed 101.

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.